Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [14C]-mazisotine in Healthy Male Participants
NCT06052462Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ly3556050 in diabetic polyneuropathy (DPN), osteoarthritis (OA) and chronic low back pain (CLBP), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered and Fecal Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered. Started Sep 2023; status: completed.
02
Drugs
ly3556050
03
Conditions
diabetic polyneuropathy (DPN)osteoarthritis (OA)chronic low back pain (CLBP)
Beyond the preview
Go deeper on NCT06052462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052462.